Profil Financier
Kiran Mazumdar-Shaw occupe actuellement le rang #1367 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $3.1 B (-$326 sur 24h).
Kiran Mazumdar-Shaw, one of India's richest self-made women, founded biopharmaceutical firm Biocon, in 1978. The firm has successfully forayed into the lucrative U.S. market, and it also has one of Asia's largest insulin factories in Malaysia's Johor region.
In December 2025, Biocon announced that it is buying the rest of privately held subsidiary Biocon Biologics to consolidate its biosimilars and generics drug businesses. The deal values Biocon Biologics at $5.5 billion.
Biocon Biologics acquired the biosimilars business of U.S. drugmaker Viatris in 2022 for $3.3 billion.
In 2022, the Central Bureau of Investigation arrested a Biocon Biologics executive and four others in an alleged bribery case. The company denied any wrongdoing.
Biocon-backed cancer therapy company Bicara Therapeutics raised $362 million in an IPO on the Nasdaq in 2024.
Mazumdar-Shaw wanted to be a doctor but couldn't get into medical school.
In 2019, she and late husband John Shaw, donated $7.5 million to the University of Glasgow to create a research hub and a professorial chair of precision oncology.
In 2024, she was bestowed the Jamsetji Tata Award by the Indian Society for Quality for pioneering biosciences movement in India.